Leap Therapeutics Inc. (LPTX) has several pivotal clinical trial milestones to watch for in the coming months, particularly regarding its lead drug candidate, DKN-01, an anti-DKK1 monoclonal antibody.
DKN-01 is being tested in combination with standard therapies for advanced colorectal and gastric cancers.
A phase II trial evaluating DKN-01 in combination with bevacizumab and chemotherapy for second-line treatment of advanced colorectal cancer, dubbed DeFianCe, is underway. Enrollment in the expanded randomized controlled Part B of the DeFianCe study has been completed, with initial results expected in mid-2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com